The diagnostic value of IRF4 and FGF23 in gingival crevicular fluid and serum for dentin hypersensitivity was compared
Sažetak
Objective: The aim of this study is to investigate the diagnostic value of interferon regulatory factor 4 (IRF4) and fibroblast growth factor 23 (FGF23) in gingival crevular fluid (GCF) and serum for dentin hypersensitivity (DH), and to analyze the relationship between IRF4, FGF23 and inflammatory factors and T lymphocyte subsets.
Methods: 24 DH patients receiving orthodontic treatment at our institution between 2022 and early 2025 were enrolled as the study cohort, along with 124 healthy controls matched for age and sex. GCF and serum samples were obtained 48 hours post-desensitization therapy to quantify IRF4 and FGF23 levels (via enzyme-linked immunosorbent assay), along with serum inflammatory markers (interleukin [IL]-1β, IL-6, high-sensitivity C-reactive protein [hs-CRP]) and T-cell subpopulations (CD3+, CD4+, CD8+). Statistical analyses included Pearson's correlation to examine relationships between IRF4/FGF23 and clinical parameters, with receiver operating characteristic (ROC) curve analysis determining diagnostic accuracy.
Results: The study revealed that GCF and serum levels of IRF4 and FGF23 were markedly elevated in DH patients compared to healthy controls (P<0.05), with a strong positive correlation between the two biomarkers (P<0.001). Diagnostic analysis revealed that GCF testing outperformed serum assessment, with the highest accuracy (AUC = 0.846) achieved through combined detection. Notably, IRF4 and FGF23 levels in gingival crevicular fluid were positively correlated with inflammatory markers (IL-1β, IL-6, and hs-CRP). Further immune profiling indicated reduced CD3+ and CD4+ T-cell populations in DH patients versus controls, with IRF4 and FGF23 levels inversely related to these T-cell subsets (P<0.05).
Conclusion: Detection of IRF4 and FGF23 in GCF is a more accurate diagnosis of DH than in serum. These findings provide new insights into the future clinical diagnosis of DH.
Sva prava zadržana (c) 2025 Can Song, Yubao Jia, Yaxuan Liu, Yujie Zhang, Jing Yu, Mengmeng Xian
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.